Hengrui Pharma(SH:600276) Zheng Quan Ri Bao Wang·2025-05-15 03:41Group 1 - The core point of the article is that Jiangsu Hengrui Medicine Co., Ltd. has officially launched its global public offering of H-shares, aiming to issue 224.5 million H-shares with a price range of HKD 41.45 to HKD 44.05 per share, potentially raising up to HKD 130.8 billion if the overallotment option is fully exercised, marking the highest fundraising amount for a Hong Kong pharmaceutical IPO in the past five years [1][2] - The public offering in Hong Kong is set to end on May 20, 2025, with the final issue price expected to be determined by May 22, and the shares may be listed on the Hong Kong Stock Exchange as early as May 23 [1] - The IPO has attracted a prestigious lineup of cornerstone investors, including the Government of Singapore Investment Corporation (GIC), Invesco, UBS Global Asset Management, Hillhouse Capital, and Boyu Capital [1] Group 2 - The funds raised from the IPO will be used for research and development plans, building new production and research facilities in China and overseas, upgrading existing production facilities in China, working capital, and other general corporate purposes [2] - The Hong Kong listing is a crucial step in the company's overseas strategy, enhancing its brand influence in the global pharmaceutical industry due to the broad base of international investors in the Hong Kong capital market [2] - The listing will optimize the company's capital structure, open new financing channels, and support diversification of financing, while also facilitating the expansion of overseas business and international research collaborations, thereby enhancing global competitiveness [2]